Advice

in the absence of a submission from the holder of the marketing authorisation:

eslicarbazepine acetate (Zebinix ®) is not recommended for use within NHSScotland.

Indication under review: As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice45KB (PDF)

Download

Medicine details

Medicine name:
eslicarbazepine acetate (Zebinix)
SMC ID:
SMC2090
Indication:
As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.
Pharmaceutical company
Eisai Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
11 June 2018